Literature DB >> 9562310

Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases.

T Sekizawa1, H Openshaw, K Ohbo, K Sugamura, Y Itoyama, J C Niland.   

Abstract

We assayed IL-6 in 105 cerebrospinal fluid (CSF) samples from patients with ALS, MS, HTLV-1 associated myelopathy (HAM), and controls. There was considerable overlap in IL-6 levels in all patient groups. The mean IL-6 in 27 patients with ALS was significantly higher than in 21 patients in the other neurological disease (OND) group (P=0.0075). There were no significant differences in MS or HAM and the OND control group. Overall, CSF IL-6 correlated with protein concentration but not with percentage IgG or IgG-albumin index. Patients with CSF oligoclonal bands were no more likely to have detectable IL-6 than patients without oligoclonal bands. Similarly, IL-6 did not correlate with clinical disease activity in MS when subgroups of patients were compared or when an individual patient was followed over time. The elevated IL-6 in ALS may reflect an ongoing humoral immune response, or IL-6 may be non-specifically expressed in these patients as a putative neurotrophic factor in response to nerve cell degeneration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9562310     DOI: 10.1016/s0022-510x(97)00228-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  44 in total

1.  Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity.

Authors:  Qiang Li; Netanya Y Spencer; Nicholas J Pantazis; John F Engelhardt
Journal:  J Biol Chem       Date:  2011-09-20       Impact factor: 5.157

Review 2.  The executioners sing a new song: killer caspases activate microglia.

Authors:  J L Venero; M A Burguillos; P Brundin; B Joseph
Journal:  Cell Death Differ       Date:  2011-08-12       Impact factor: 15.828

Review 3.  Gender differences in neurological disease: role of estrogens and cytokines.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 4.  [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].

Authors:  K Kollewe; R Dengler; S Petri
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

Review 5.  Inflammation in ALS and SMA: sorting out the good from the evil.

Authors:  Dimitra Papadimitriou; Virginia Le Verche; Arnaud Jacquier; Burcin Ikiz; Serge Przedborski; Diane B Re
Journal:  Neurobiol Dis       Date:  2009-10-13       Impact factor: 5.996

6.  Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model.

Authors:  Rengang Wang; Bo Yang; Dongxian Zhang
Journal:  Glia       Date:  2011-03-28       Impact factor: 7.452

Review 7.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 8.  Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.

Authors:  Kevin M Budge; Matthew L Neal; Jason R Richardson; Fayez F Safadi
Journal:  Mol Neurobiol       Date:  2017-08-30       Impact factor: 5.590

9.  Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.

Authors:  Elijah W Stommel; Jeffrey A Cohen; Camilo E Fadul; Christopher H Cogbill; David J Graber; Linda Kingman; Todd Mackenzie; Jacqueline Y Channon Smith; Brent T Harris
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 10.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.